Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 3/20 | 0.59 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.57 |
| ▸ | PLAU | P00749 | 4/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.54 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | LDLR | P01130 | 1/20 | 0.50 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20756513 | 1.00 | CTSG (0.59) | CTSGEPHA2PLAUOPRK1KLKB1 | |
| SCHEMBL20756136 | 0.96 | CTSG (0.55) | CTSGEPHA2PLAUOPRK1KLKB1 | |
| SCHEMBL20756692 | 0.96 | CTSG (0.56) | CTSGEPHA2PLAUOPRK1KLKB1 | |
| SCHEMBL20756630 | 0.95 | KLKB1 (0.55) | CTSGEPHA2PLAUKLKB1PLG | |
| SCHEMBL21959057 | 0.95 | CTSG (0.54) | CTSGEPHA2PLAUOPRK1KLKB1 | |
| SCHEMBL24245867 | 0.94 | OPRK1 (0.53) | CTSGEPHA2PLAUOPRK1KLKB1 | |
| SCHEMBL20756148 | 0.94 | KLKB1 (0.54) | CTSGEPHA2PLAUKLKB1PLG | |
| SCHEMBL20756327 | 0.94 | KLKB1 (0.54) | CTSGEPHA2PLAUKLKB1PLG | |
| SCHEMBL20763401 | 0.94 | KLKB1 (0.55) | CTSGEPHA2PLAUKLKB1PLG | |
| SCHEMBL20763007 | 0.94 | CTSG (0.52) | CTSGEPHA2PLAUOPRK1KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200215199-A1 | COMPOUNDS FOR TREATING CANCER | BICYCLETX LIMITED (GB) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200215199-A1 | COMPOUNDS FOR TREATING CANCER | TP53, VHL, MYC | CTSG 411/4885EPHA2 1788/4885PLAU 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.